Treatment of endotoxaemia

• US 4,107,305 A
• Filed: 08/04/1975
• Issued: 08/15/1978
• Est. Priority Date: 08/04/1975
• Status: Expired due to Term

• Current Assignee: ED. Geistlich Soehne AG Fuer Chemische Industrie
• Original Assignee: ED. Geistlich Soehne AG Fuer Chemische Industrie
• Inventors: Pfirrmann, Rolf W.
• Primary Examiner(s): Goldberg, Jerome D.
• Application Number:
  US05/601,716
• Time in Patent Office: 1,107 Days
• Field of Search: 424/246
• US Class Current: 514/222.5
• CPC Class Codes: A61K 31/54 having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame

Abstract

The present invention provides a method of combatting endotoxaemia whereby there is administered to a patient an effective amount of a compound of the formula: ##STR1## where R¹ is hydrogen or an alkyl group with 1-6 carbon atoms and R² is hydrogen or an alkyl group with 1-6 carbon atoms or a group of formula: ##STR2## R¹ is preferably hydrogen and R² is preferably hydrogen or a group of formula II; the most preferred compound is bis-(1,1-dioxo-perhydro-1,2,4-thiadiazin-4-yl)-methane.

Claims

1. A method for treating a patient suffering from endotoxaemia wherein an effective amount to reduce or eliminate endotoxaemia of a compound of the formula:

##STR5## where R¹ is hydrogen or alkyl having 1-6 carbon atoms is administered to said patient.

2. A method as claimed in claim 1 in which said active compound is administered to a patient suffering from faecal peritonitis.

3. A method as claimed in claim 2 in which the said active compound is administered by introduction directly into the abdomen of the patient.

4. A method as claimed in claim 1 in which the said active compound is administered at a dose level between 1 and 6 g per patient.

5. A method as claimed in claim 2 in which the said active compound is administered at a dose level between 2 and 4 g per patient.

6. A method as claimed in claim 1 in which the said active compound is administered in solution or suspension in a sterile, pyrogen-free parenterally acceptable aqueous vehicle.

7. A method as claimed in claim 6 in which the concentration of said active compound in the vehicle is between 1.0% and 2.5%.

8. A method for treatment of endotoxaemia as claimed in claim 1 in which said active compound is bis-(1,1-dioxo-perhydro-1,2,4-thiadiazin-4-yl)-methane.

9. A method as claimed in claim 1 for the treatment of osteomyelitis exhibiting endotoxic conditions whereby an effective amount of said active compound is administered to a patient suffering from osteomyelitis.

10. A method as claimed in claim 1 wherein said active compound is administered by irrigation into a body cavity during surgery to cure endotoxaemia.